Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer. Research published in the November issue of The Journal of Nuclear Medicine found that the ...
Nov 6, 2018
0
0
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work ...
Jan 29, 2013
0
0
(HealthDay)—In the United States, more patients are being diagnosed with stage I non-small cell lung cancer (NSCLC), and five-year survival for NSCLC has increased, according to a study published online Oct. 21 in JAMA ...
Nov 3, 2021
0
1
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone ...
Nov 28, 2012
0
0
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published ...
Aug 14, 2012
0
0
(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according ...
Jul 27, 2021
0
1
The U.S. Food and Drug Administration today approved a new drug to treat non-small-cell lung cancer (NSCLC), offering patients new hope in fighting this difficult disease. Lung cancer is expected to lead to over 150,000 deaths ...
Dec 15, 2014
0
0
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 ...
Oct 17, 2012
0
0
Lung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of these, 30 to 40 percent are considered locally advanced and are ...
Dec 17, 2019
0
3
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published ...
Nov 21, 2012
0
0
